ArticleBMC infectious diseases2025
Leveraging injection networks to prevent HIV and other blood borne infections among people who inject drugs in Kenya: design and rationale.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gender differences in social networks of women and men who inject drugs in Kenya.The International journal on drug policy · 2026Article
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
backgroundHIV and Hepatitis C (HCV) are blood borne infections (BBIs) that remain a significant cause of global morbidity and mortality among people who inject drugs (PWID). UNAIDS and WHO have set goals for the elimination of viral hepatitis and HIV as major public health threats by 2030. To achieve these targets, innovative strategies are required among marginalized populations such as PWID, especially in resource-limited countries where coverage of harm reduction services is often limited. The goal of this study is to inform targeted strategies to prevent transmission of BBIs among PWID.
methodsWe will use respondent driven sampling (RDS) to recruit PWID from needle and syringe programs in Kenya. Participants will complete biobehavioral and social network surveys and receive point-of-care HCV, HIV, and hepatitis B (HBV) testing. Participants will return for at least one follow-up visit to complete additional surveys and testing. We will use network data from RDS, egocentric, and viral phylogenetics to identify how highly central PWID contribute to transmission networks and use mathematical modelling to investigate the impact of targeted interventions based on network characteristics. DISCUSSION: This study will provide important information for policymakers and researchers designing strategies for BBI elimination. Network- and molecular epidemiologic-informed tools to guide targeted strategies may be critical to maximizing the impact of treatment and prevention efforts in resource-limited settings. This approach may provide a durable template for future studies, including prospective assessments of targeted prevention and elimination strategies among PWID, and assist with monitoring elimination progress in resource-limited settings.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.